ZCZC
BFF-49
HEALTH-VIRUS-EU-VACCINE-ASTRAZENECA
Confusion over AstraZeneca-EU talks on vaccine delay
BRUSSELS, Jan 27, 2021 (BSS/AFP) – Confusion erupted on Wednesday over a
scheduled meeting between AstraZeneca and the EU to discuss the
pharmaceutical group’s delay in delivering its Covd-19 vaccine.
An EU official told AFP that AstraZeneca had abruptly pulled out of the
meeting — the third called for this week — in what was seen as an
escalation in the contractual row over the deliveries.
But shortly afterwards AstraZeneca issued a statement saying: “We can
confirm we have not pulled out, we will be attending the meeting with EU
officials later today (Wednesday).”
It was not immediately clear if AstraZeneca had reversed a decision to
pull out, or if the EU’s information that it would not participate was
incorrect.
A European Commission spokeswoman, Dana Spinant, told journalists the
situation with AstraZeneca executives was “evolving”.
“I can’t say whether AstraZeneca will be represented,” she said, adding
that some input was expected from the firm during the meeting.
Public communication on the issue has become increasingly sharp.
The European Commission is demanding AstraZeneca fulfil its contract for
the vaccine doses.
But AstraZeneca CEO Pascal Soriot said in an interview given on Tuesday
that his firm was bound only to make its “best effort” to deliver the doses.
“We didn’t commit with the EU… It’s not a commitment we have to Europe,”
he said.
He also said that former EU member Britain — which has been rolling out
AstraZeneca vaccine jabs at a high pace — had a headstart on the European
Union by signing its contract three months earlier, giving time to iron out
“glitches” in UK vaccine plants.
A senior EU official on Wednesday rejected those points made by Soriot.
“We contest many of the things in the interview, including the idea that
the factories in the UK are reserved for UK deliveries. It’s not true,” the
EU official told AFP.
– ‘Unsatisfactory’ answers –
Wednesday’s meeting was the third scheduled this week between the EU and
AstraZeneca representatives.
The first two, both on Monday, resulted in the EU being given
“unsatisfactory” answers, European health commissioner Stella Kyriakides said
afterwards.
While Soriot revealed some of the terms of the contract signed with the
European Commission, the full contract remains confidential at AstraZeneca’s
demand.
The Commission was to brief journalists in further detail on its response
and on the increasingly bitter feud that has erupted with the pharmaceutical
firm.
The delay, coming on top of one announced two weeks ago by
BioNTech/Pfizer, threatens to scupper the Commission’s goal of having 70
percent of all adults in the EU vaccinated against Covid-19 by the end of
August.
Already the rollout of jabs is trailing well behind Britain, the United
States and Israel on a per capita basis. Two vaccines are currently
authorised for use across the 27-nation bloc: the BioNTech-Pfizer and Moderna
jabs.
The European Medicines Agency is expected to approve the AstraZeneca
vaccine late this week.
BSS/AFP/SSS/1833 hrs